A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
NCT01265927
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Breast Neoplasms
Interventions
DRUG:
GRN163L in combination with trastuzumab
Sponsor
Indiana University
Collaborators
[object Object]
[object Object]